Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.
Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that IL-17 alone or in combination with B cell-activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This effect was mediated mainly through the nuclear factor-kappaB-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance correlated with the disease severity of systemic lupus erythematosus.
Doreau
Agnès
A
Université de Lyon, Institut Fédératif de Recherche 128, Lyon, France.
Belot
Alexandre
A
Bastid
Jérémy
J
Riche
Benjamin
B
Trescol-Biemont
Marie-Claude
MC
Ranchin
Bruno
B
Fabien
Nicole
N
Cochat
Pierre
P
Pouteil-Noble
Claire
C
Trolliet
Pierre
P
Durieu
Isabelle
I
Tebib
Jacques
J
Kassai
Berhouz
B
Ansieau
Stéphane
S
Puisieux
Alain
A
Eliaou
Jean-François
JF
Bonnefoy-Bérard
Nathalie
N
D018941:Antigens, CD19 / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D053264:B-Cell Activating Factor / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007136:Immunoglobulins / Q000378:metabolism; D020381:Interleukin-17 / Q000097:blood* / Q000235:genetics / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000473:pathology; D008297:Male; D015778:Minor Histocompatibility Antigens; D016328:NF-kappa B / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D051879:Twist-Related Protein 1 / Q000235:genetics / Q000378:metabolism
D018941:Antigens, CD19; D053264:B-Cell Activating Factor; C096816:BCL2-related protein A1; D007136:Immunoglobulins; D020381:Interleukin-17; D015778:Minor Histocompatibility Antigens; D016328:NF-kappa B; D009687:Nuclear Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D012097:Repressor Proteins; C103173:TWIST1 protein, human; C486274:TWIST2 protein, human; D051879:Twist-Related Protein 1